Señales en vivo de AMYT.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 dic 1970 @ 19:00):

Stats
Volumen de hoy	90 627.00
Volumen promedio	164 181
Capitalización de mercado	0.00
EPS	£-0.0651 ( 2021-09-29 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.0400
ATR14	£0 (0.00%)

Amryt Pharma Holdings Ltd Correlación

10 Correlaciones Más Positivas
NESF.L	0.894
MNTN.L	0.886
AAL.L	0.865
FSFL.L	0.859
CLX.L	0.859
LRE.L	0.857
CPX.L	0.85
GROC.L	0.847
MCM.L	0.847
LXI.L	0.837

10 Correlaciones Más Negativas
UNG.L	-0.842
RAI.L	-0.838
ADT.L	-0.838
BBB.L	-0.833
CIZ.L	-0.83
KITW.L	-0.822
RKH.L	-0.817
TFG.L	-0.815
DRGN.L	-0.811
RDSA.L	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amryt Pharma Holdings Ltd Finanzas

Annual	2020
Ingresos:	£182.61M
Beneficio Bruto:	£63.58M (34.82 %)
EPS:	£-1.378

FY	2020
Ingresos:	£182.61M
Beneficio Bruto:	£63.58M (34.82 %)
EPS:	£-1.378

FY	2019
Ingresos:	£58.12M
Beneficio Bruto:	£16.12M (27.74 %)
EPS:	£-0.860

FY	2018
Ingresos:	£16.53M
Beneficio Bruto:	£10.47M (63.35 %)
EPS:	£-0.644

Financial Reports:

No articles found.

Amryt Pharma Holdings Ltd

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.